Goldman Sachs Maintains Top Rating on Pfizer (PFE), Catalysts Ahead and Possible Full Break-Up
Go back to Goldman Sachs Maintains Top Rating on Pfizer (PFE), Catalysts Ahead and Possible Full Break-Up| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 67.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.61 | 52 Week High | $77.12 | |||
| Open | $67.61 | 52 Week Low | $49.03 | |||
| Day High | $67.61 | P/E | 43.90 | |||
| Day Low | $67.61 | EPS | $1.54 | |||
| Volume | 873 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 28.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.24 | 52 Week High | $37.39 | |||
| Open | $28.24 | 52 Week Low | $28.25 | |||
| Day High | $28.24 | P/E | 17.12 | |||
| Day Low | $28.24 | EPS | $1.65 | |||
| Volume | 125,074 | |||||
